New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...

RESEARCHERS from the University of Cincinnati, Ohio, suggest that increasing levels of the brain protein amyloid-β 42 (Aβ42) ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

The other hallmark of the disease, Amyloid-beta (Aβ) peptides 42 (Aβ42) and 40 (Aβ40), are released from cells and are prone to aggregate, depositing in the brain as amyloid plaques. These proteins ...

Three months after treatment with troculeucel, two patients in the Phase I portion went from having moderate to mild symptoms of dementia.

Caffeine and Alzheimer disease risk appear to be linked, as lower caffeine intake is associated with Alzheimer disease biomarkers.

A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...

A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid ...